The most common cause of chronic diarrhea in cats is inflammatory bowel disease (IBD). This condition is thought to be the result of a disruption in the normal function of intestinal tract cells and the immune system. Additionally, these cells interact with dietary constituents and organisms in the lumen of the digestive tract, resulting in chronic inflammation and poor intestinal function. This leads to persistent diarrhea, often accompanied by weight loss, vomiting, and decreased appetite. Owners of these unfortunate cats are often asked to give multiple medications to their pets on a daily basis. This situation may persist for the life of the pet, and sometimes diarrhea control is inadequate. The quality of life of both pet and owner is significantly affected. A form of stem cell therapy known as mesenchymal stromal cells (MSC) has come to the forefront in recent years as a potential therapeutic option for chronic inflammatory diseases. This cell therapy helps correct abnormalities in the immune system that leads to this inflammation. Previous research in this laboratory has shown that feline adipose-derived MSC (fMSC) can be easily generated in large quantities from a small amount of adult tissue, such as adipose or fat, and then safely administered back to diseased cats with no notable side effects. This study proposes to evaluate the use of adipose-derived fMSC as a treatment for feline IBD.